- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07792694
Predict Arrhythmia Risk Using Intelligent Software (PARIS)
Artificial Intelligence-based Prediction and Detection of Critical Arrhythmias in Acute Cardiac Illness.
Cardiac arrhythmias frequently occur in patients admitted to the Coronary Care Unit (CCU). The majority of these patients are treated for an acute myocardial infarction, which carries an increased risk of life-threatening arrhythmias such as ventricular tachycardia (VT) or ventricular fibrillation (VF). This risk is one of the reasons these patients are monitored for 48 hours after a myocardial infarction, in accordance with the guidelines of the European Society of Cardiology (ESC) for acute coronary syndrome. Other arrhythmias, such as asystole, atrial fibrillation, or atrioventricular block, also occur in CCU patients. These arrhythmias are recorded on the electrocardiogram (ECG) monitor in the CCU and trigger an alarm for healthcare staff. However, in order to apply this alarming with sufficient sensitivity, many false positive alarms are also produced, which increases the workload for nurses (alarm fatigue) and undermines patient well-being.
This study will investigate whether Artificial Intelligence (AI) models, using continuous ECG data, can help improve the prediction of patients at risk of a life-threatening cardiac arrhythmia. Firstly, this study will aim to predict patients at risk of VT/VF in both the short term (30 minutes) and long term (1 day) in patients under continuous telemetric monitoring. This prediction facilitates timely intervention by the team in the short term, and in the long term, the safe transfer of a patient to a lower-complexity ward or earlier safe discharge of a patient. Secondly, this study will aim for improved detection to reduce the number of false negative alarms and thereby reduce alarm fatigue.
The performance of these AI models can be evaluated through this retrospective observational study. Patients aged 18 years or older who have been admitted with acute cardiac disease will be included. The primary objective of this study will be to evaluate the performance of AI models that detect and predict critical arrhythmias in the short and long term, using ECG data obtained via the monitoring system.
Visão geral do estudo
Status
Descrição detalhada
Primary objective:
Assessment of the performances of AI models in identifying patients at risk of sustained VT and VF from bedside monitor ECG in different timeframes:
- 30-minute prediction model
- 1-day prediction model
Secondary objectives:
• Assessment of potential healthcare savings if the AI model in would be used in clinical practice, such as CCU length-of-stay (CCU-LOS), hospital length-of-stay and associated costs
Exploratory objectives:
- Real time and continuous detection of events for alarming
- Prediction of other types of arrhythmias (e.g., Atrial fibrillation (AF), atrioventricular block, severe brady-arrhythmia) using in hospital ECG monitoring.
- Identification of clinical risk factors for sustained VT and/or VF
- Exploration of development and assessment of new AI models using new (clinical) input
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Maud E Kortman, M.D.
- Número de telefone: 040 239 9111
- E-mail: maud.kortman@catharinaziekenhuis.nl
Estude backup de contato
- Nome: Luuk C Otterspoor, Dr. M.D.
- E-mail: luuk.otterspoor@catharinaziekenhuis.nl
Locais de estudo
-
-
North Brabant
-
Eindhoven, North Brabant, Holanda, 5623 EJ
- Recrutamento
- Catharina Hospital Eindhoven
-
Contato:
- Maud E Kortman, M.D.
- Número de telefone: 040 239 9111
- E-mail: maud.kortman@catharinaziekenhuis.nl
-
Investigador principal:
- Luuk C Otterspoor, Dr. M.D.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion criteria:
- Patients admitted from 1/1/2023*
- Patients aged 18 years or older
- Admitted for acute cardiac illness or after elective cardiac procedures
- Who are on ECG monitoring in the CCU, ICU or ward
Patients for whom continuous waveform ECG data have been routinely stored.
- Continuous waveform ECG data has been routinely stored in the CZE since 1/1/2023 on the ICU, since 1/12/2025 on the CCU and on the ward it has yet to be implemented. As our project utilizes this continuous ECG data, it will only include patients for whom this data is available.
Exclusion Criteria:
- Patients who expressed their preference for not having their data used for scientific research or to improve quality of care in the opt-out program of the CZE.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Adult patients admitted for acute cardiac illness/elective cardiac procedures on ECG monitoring
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Occurrence of sustained ventricular tachycardia or ventricular fibrillation
Prazo: During admission
|
The primary outcome of the study is the occurrence of sustained ventricular tachycardia (VT) (monomorphic and polymorphic with a heartrate > 100 bpm and duration > 30 seconds or with hemodynamic compromise such as fainting or need for resuscitation) or ventricular fibrillation.
(Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Secondary outcome measure
Prazo: During admission
|
- A 'textbook' outcome (no adverse events) (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Secondary Outcome Measure
Prazo: during admission
|
- In-hospital onset and offset of cardiac arrhythmias (e.g.
atrial fibrillation, atrio-ventricular block or severe tachy- or bradyarrhythmia, non-sustained VT).
(Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
during admission
|
|
Secondary outcome measure
Prazo: During admission
|
- In hospital death/cardiovascular in-hospital death (include cause if available) (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Secondary outcome measure
Prazo: During admission
|
- Pulseless electrical activity (PEA) and asystole (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Performance of AI prediction model
Prazo: During admission
|
Discrimination of AI prediction model expressed with Area Under the Receiver Operating Characteristic curve (AUROC), Area Under the Precision-Recall Curve (AUPRC), sensitivity, specificity, (Positive Predictive Value) PPV and (Negative Predictive Value) NPV
|
During admission
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Luuk C Otterspoor, Dr. M.D., Catharina Ziekenhuis Eindhoven
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- nWMO-2025.186
- project code 24PPS046 (Número de outro subsídio/financiamento: National collaboration: Holland High Tech, Eindhoven University of Technology, Catharina Hospital Eindhoven, Philips)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .